Immunome shares soar on positive testing data for its experimental Covid therapy
Immunome's stock rose nearly 13% in Thursday morning trading after reporting positive preclinical data for its experimental Covid-19 therapy.
The Exton biopharmaceutical company said the data shows the combination of two antibodies, IMM20253 and IMM20184, in its Covid-19 three-antibody cocktail successfully neutralized the omicron variant in testing on hamsters.
Additionally, Immunome said studies involving a SARS-CoV-2 pseudovirus als o show that IMM20253 successfully neutralized the omicron subvariant.…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: John George Source Type: news